Internal Medicine, Endocrinology, Diabetes, & Metabolism · Salem, VA
NPI
1356306591
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1802 Braeburn Dr
Salem, VA, 24153
Phone (540) 772-3490
Groups this clinician bills Medicare through
Medicare paid, 2024
$188K
6,128 services
Medicare patients, 2024
470
Average age 74
Drug cost, 2024
$1.2M
4,728 prescriptions
Company payments, 2025
$191
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kamran Rasul was code J0897 (injection, denosumab, 1 mg), 3,960 times for 40 patients. In total Kamran Rasul billed 6,128 services in 19 codes, and Medicare paid $188K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,960 | 40 | $20.60 | $82K |
| 99214 Office E&M - Established | Office | 816 | 434 | $96.58 | $79K |
| 96372 Injection Administration | Office | 75 | 45 | $11.63 | $873 |
| 95251 Test - Miscellaneous | Office | 74 | 27 | $27.10 | $2,005 |
| 99204 Office E&M - New | Office | 45 | 45 | $130.26 | $5,862 |
| 99215 Office E&M - Established | Office | 34 | 31 | $141.10 | $4,797 |
| 99213 Office E&M - Established | Office | 23 | 20 | $75.86 | $1,745 |
By year: 2022 $193K for 6,891 services; 2023 $171K for 5,438 services; 2024 $188K for 6,128 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kamran Rasul prescribed most often to Medicare patients was Levothyroxine Sodium, with 878 prescriptions and refills. In total Kamran Rasul wrote 4,728 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 878 | 2,093 | 211 | $7,787 |
| Synthroid Levothyroxine Sodium | 388 | 861 | 82 | $32K |
| Ozempic Semaglutide | 224 | 262 | 28 | $248K |
| Metformin Hcl Generic | 202 | 522 | 56 | $830 |
| Jardiance Empagliflozin | 141 | 200 | 21 | $117K |
| Atorvastatin Calcium Generic | 135 | 343 | 34 | $1,091 |
| Mounjaro Tirzepatide | 132 | 152 | 25 | $158K |
| Methimazole Generic | 126 | 195 | 27 | $572 |
| Metformin Hcl Er Metformin Hcl | 114 | 266 | 31 | $912 |
| Hydrocortisone Generic | 108 | 126 | 21 | $3,836 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 100 | 204 | 32 | $23K |
| Trulicity Dulaglutide | 100 | 118 | 14 | $114K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 85 | 149 | 27 | $7,904 |
| Rosuvastatin Calcium Generic | 84 | 164 | 20 | $472 |
| Pioglitazone Hcl Generic | 71 | 137 | 15 | $641 |
Brand drugs: 2,153 claims; generic drugs: 2,287 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kamran Rasul $191 ($191 in general payments such as food, travel and fees) from 6 companies. The largest payer was Beta Bionics, Inc. with $45.05.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.